Field report N-39 / Q1 · sheet /deals
M&A & DealsFiled from the territory
Aetna's Ex-CEO Says CVS Bought His Company to Hide Unfixed Problems
Mark Bertolini says CVS's near-$70 billion Aetna deal masked problems 'they never really fixed'—weeks after CVS announced its breakup, shedding $15 billion in market value.
- Grid
- N-39 / Q1
- Surveyed
- November 18, 2026
- Reading
- 4 min read
- Correspondent
- Sophie Lindqvist

Field notes
- CVS bought Aetna for almost $70 billion in 2018; Bertolini called the deal cover for unfixed problems on Nov. 17
- CVS will spin off ~9,000 stores and MinuteClinic as CVS Pharmacy by the first half of 2028; shares fell 12.5% on Nov. 4, wiping out nearly $15 billion
- Oscar Health posted Q3 net income of $167.3 million on revenue of $5.14 billion, up 72%
- Bertolini says 74% of large employers now consider defined-contribution health coverage
- Oscar reports 67% of coding done by AI agents and $1.2 billion cut from operating costs over three years
Mark Bertolini, the man who sold Aetna to CVS Health for almost $70 billion in 2018, said on Monday that the deal's real purpose was concealment — and that the acquisition would not happen today. His comments come two weeks after CVS announced it will break itself in two.
"The real intention" of the purchase, Bertolini said at the Fortune 500 Innovation Forum in Detroit, "was just to take the earning stream and revenue stream from [Aetna] to hide a bunch of other things that they never really fixed." He tied the claim directly to the breakup: "You'd never do that deal now." CVS declined to comment on the remarks.
The accusation deserves scrutiny. Bertolini led Aetna from 2011 through the sale and now runs Oscar Health. He left the CVS board in February 2020 as it shrank from 16 directors to 13, telling the Wall Street Journal at the time he was pushed out before the Aetna integration finished. A CVS spokesperson then said the board felt it was the right time for him to focus on other endeavors. His account of the deal's motives is that of a departed executive, not a disinterested observer.
What does the split change for employers and patients?
CVS will keep Aetna and Caremark, its pharmacy benefit manager (a company that negotiates drug prices between insurers, pharmacies and manufacturers), and spin off roughly 9,000 stores and MinuteClinic as a separate company, CVS Pharmacy, by the first half of 2028. The market's verdict on the Nov. 4 announcement was unambiguous: CVS shares closed down 12.5%, erasing nearly $15 billion in market value.
For employers, insurers and anyone with a pharmacy benefit, the move partially unwinds the largest bet on vertical integration (one company owning insurer, PBM and retail pharmacy) in American health care. Morningstar analyst Julie Utterback noted "CVS has the most exposure to vertical integration in the industry."
CVS frames the split as strength, not retreat. "This is the right decision, at the right time," spokesperson David Whitrap said in a statement, adding that the company is "getting ahead of the external market dynamics from a position of strength. Each of our businesses are thriving." CEO David Joyner told Reuters: "The businesses are running really well. We've been afforded the opportunity to make different decisions than I could have two years ago." A company shedding $15 billion in a day would presumably describe it that way regardless.
What happened to the 'front door'?
The original pitch was retail medicine. Bertolini said the Aetna deal was meant to create "a new front door for health care," with customers shopping for care inside CVS stores — in 2017 he pitched "10,000 new front doors to the health care system." That vision "never got pulled through because it took a lot of intensity to do it," he said, and after he moved to the board, the strategy stalled. On succession he was blunt: "There can only be one CEO."
The stores — the front door of the pitch — are now the piece CVS is cutting loose. Bertolini argued the concept stopped making sense after the pandemic and the shift to virtual care. He also offered what he called an admission against self-interest: he helped take Express Scripts public when "we thought the PBM was a great idea," comparing the industry's persistence to a street-corner card hustle. "Where's the queen?"
What would he fix? End employer coverage
Asked what he would remove from the system, Bertolini answered: "Eliminate employer-sponsored health insurance." His logic is bargaining power — doctors, hospitals and insurers consolidated, so an employer with 20,000 or 30,000 workers that once secured strong network rates no longer can. He cited a figure of 74% of large employers now considering defined contribution, where workers receive a set sum instead of a chosen plan, and wants that money in portable accounts such as HSAs or HRAs that follow workers across jobs and into Medicaid or Medicare.
Employers are already paying heavily for the current model. Family premiums for employer coverage passed $28,000 in 2026, with workers contributing $7,471, according to KFF's annual survey.
Zach Reitano, CEO of cash-pay telehealth company Ro, shared the stage and agreed on the diagnosis: "Most frequently in the healthcare system, the patient is not the customer," producing "suboptimal outcomes just based on incentives."
Bertolini's own numbers at Oscar give his critique standing. The insurer, which sells mainly on Affordable Care Act exchanges, reported third-quarter net income of $167.3 million against a $137.5 million loss a year earlier, on revenue of $5.14 billion, up 72%. Membership stood near 2.69 million. Onstage he claimed 67% of Oscar's coding is done by AI agents, that it runs 40 large language models, and that it has removed $1.2 billion from operating costs over three years — claims worth auditing, but stated plainly. "Americans always pick the best solution last," he said.
CVS expects to complete the separation in the first half of 2028. Aetna stays with Caremark. The front door stands alone.
via fortune.com/feed/ (Source)
More from Sophie Lindqvist
Show full bio
Correspondent covering money, funding and market shifts around corporate strategy and chief-executive leadership at CEO Frontier.
483 articles
Adjacent sheets
- Prediction markets favor Jensen Huang’s continued Nvidia tenure
- Nvidia’s $450 Billion Drop Puts CEO Spy Risk in Focus
- Lucid Misses Q3 Estimates, Draws Further $1.75 Billion From Saudi Backer
- PitchBook Names BILL, Rapid7 and First Advantage as Top Take-Private Targets
- Nvidia Loses $300 Billion in Hours as Board Weighs Ousting Huang